|
||
|
Re: Gast-Kommentar meinerseits | |||
Antwort zu Re: Informationen zu Thyroxin u. Haarausfall bei Hashimoto von SG | |||
Antworten | Erster Beitrag | Forum |
Da ist natürlich vieles Falsch in SG s Aussage. So etwas passiert wenn Laien glauben das ihre Erkrankung sie zu Professoren stempelt!!
Bei postmenopausalen Frauen bringt bei bestehendem typischen postmenopausalen Haarausfall eine Behandlung mit Finasterid rein gar nichts.Das ist so,weil in diesem Lebensabschnitt u.a das Haut und haarspezifische Hormon T3 abfällt.Fällt das t3 ab,entfällt auch ein wichtiger Regulator für die Haarausfall-Genetik.Drogen wie Finasterid sind dann viel zu schwach,um andere antiapoptotische Substanzen als Ersatz für T3 upzuregulieren.Das kann man dann nur noch mit starken Antiandrogenen bekämpfen,T3 ginge warscheinlich auch,wenn man es mit Östrogenen und Antiandrogenen kombiniert,nur wird diese Form der Hormonersatztheraphie von ärztlicher Seite abgelehnt!Ich lehne das auch ab,weil ich es für sehr gefährlich halte!
>Hallo,
Hier siehst du das Thyroxin auch bei androgenetischer Alopezie erwiesenermassen haarausfallwirksam ist.Also ist deine Behauptung,das Thyroxin nicht als Haarwuchsmittel bei anderen Haarerkrankungen fungieren kann falsch! Dermatol Online J. 2003 Feb;9(1):4. Related Articles, Links
Lindenbaum ES, Feitelberg AL, Tendler M, Beach D, Gamliel-Lazarovich A, Har-Shai Y, Hirshowitz B. Androgenetic Alopecia (AA) afflicts a large part of the population and of the many treatments available today none is completely satisfactory. Testing the efficacy and safety of a novel topical treatment for AA which is based on cell culture medium supplemented with insulin, thyroxin and growth hormone (CCM). The 48 participants classified as androgenetic alopecia Type II, III or IV on the Hamilton scale, concluded a randomized, vehicle-controlled, double-blind trial of 6 months duration. Under occlusive cover the gel was self applied for at least 3 hours daily. Evaluation was based on hair counts, investigator global assessment and participants self-administered questionnaire. Cessation of hair loss was reported by most participants within 28 weeks, and further confirmed by the hair count (HC) in ~80% of participants. Moreover, as early as 4 months after the start of the treatment, a time dependent increase of up to 50% in HC was observed. The average change in HC between the two groups differed significantly (p=0.007), with values of 4.1% for control and 13.8% for CCM. Following 4 months of treatment, a time dependent increase in HC (>10%) above minimal was observed in 55% of the CCM and 25% of the control and this trend continued. At 6 months 63% of the CCM and 33% of the control group exhibited increase of HC higher than 10%. The average increase in HC in the CCM and the control groups was 17.1% and 8.9% respectively (p=0.035). Self evaluation questionnaires revealed a time dependent increase in satisfaction in the CCMusers compared to the control. While the average score at T2 was similar in CCM and control (2.7 and 2.6 respectively), the score at T6 in the CCM increased to 5.9 and decreased to -0.4 in the control (p=0.007). Global-clinical evaluation following six months treatment revealed significantly (p=0.02) more hair loss in the control group (40%) compared to the CCM (7%) treated group. CCM was found effective in treating androgenetic alopecia in men. It induced cessation of hair loss, increased rate of hair growth and appearance of new hair. No side effects were reported or observed. Publication Types:
PMID: 12639462 [PubMed - indexed for MEDLINE] Here again,..in vivo and mouse..
Safer JD, Fraser LM, Ray S, Holick MF. Department of Medicine, Boston University School of Medicine, Massachusetts 02118, USA. jsafer@bu.edu The skin is a classic target tissue for thyroid hormone action. Although the histology of skin in hypothyroid states is well documented, the literature contains little assessment of skin in thyrotoxic states. In light of the paucity of information on skin under the influence of excess thyroid hormone, we investigated the direct effect of thyroid hormone on skin. Triiodothyronine (T3) was applied topically daily in liposomes to SKH-1 hairless mice for 7 days and to CD rats for 2 weeks. There was a dose-dependent increase in epidermal proliferation, dermal thickening, and hair growth in T3-treated animals. Mice that received 3.8 microg of T3 had 42% more hairs per millimeter than controls (p < 0.01), hair length that was 1,180% longer (p < 0.001), 49% greater epidermal 3H-thymidine incorporation (p < 0.01), and 80% more 5-bromo-2'-deoxyuridine (BrdU) stained cells (p < 0.05). Rats receiving 12.8 microg T3 had 48% greater dermal thickness than controls (p < 0.001), 26% greater epidermal thickness (p < 0.001), 85% more hairs per millimeter (p < 0.005), and 130% greater 3H-thymidine incorporation into the epidermis (p < 0.01). Thus, topically applied thyroid hormone has dramatic effects on both skin and hair growth. These observations offer a new strategy for developing thyroid hormone and its analogues for treating disorders of skin and hair growth. PMID: 11525263 [PubMed - indexed for MEDLINE]
Engelhard A, Christiano AM Exp Dermatol 2004 Apr;13(4):257-64.
The hair cycle is an extraordinarily complex process relying on spatially and temporally coordinated integration of intercellular signaling, cell division and death, cell migration, and gene expression. The hairless gene (hr) is expressed with hair-cycle-dependent kinetics, and pathogenic mutations in hr are responsible for the hairless and rhino phenotypes in mice and atrichia with papular lesions in humans. In addition to its expression in the skin and hair follicle, hr is also highly expressed in the brain, yet the factors governing its differential cell-type-specific expression have not yet been defined. A thyroid hormone responsive element was previously identified in the rat hr promoter which confers thyroid hormone (T3) responsiveness to heterologous promoter constructs; however, prior studies have not focused on the hr promoter itself. The hairless promoter was cloned, and it is shown that the hr promoter is transactivated by T3 in neuroblastoma cells but not in keratinocytes. Therefore, while T3 has a significant role in the regulation of neuronal expression of hairless, its upregulation in keratinocytes is T3 independent. Furthermore, hr is subject to cell-type-specific negative autoregulation, inhibiting the activity of its own promoter in keratinocytes but not neuroblastoma cells. These findings illustrate a molecular distinction between the regulation of hr expression in defined cell populations. Auch wenn die Studien in dem dir so verhassten Englisch verfasst sind liebe B,..heisst das noch lange nicht,das sie böse sind!Aber Menschen sind ja generell so,weil sie das Wesen einer Spinne oder Schlange nicht verstehen können,gelten diese Tiere als Sinnbilder des Bösen.So handhaben es dann auch medizinisch nichtversierte Menschen die in der Schule kein Englisch gelernt haben.
gruss Tino |
verfasst von: tino ® 09/20/2004, 01:30:00 |
Antworten | Spam Alarm | | Orientierung Original-Nachricht Erster Beitrag Zum Forum |
|